Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 18, 2025
Politics, Policy & Law

FTC calls out PBM price gouging of specialty generic drugs

Report says Big 3 PBMs mark up 22% of specialty generics by more than 1,000%
BioCentury | Nov 16, 2023
Deals

Nov. 16 Quick Takes: Q32 takes merger route to NASDAQ via Homology deal

Plus: SpringWorks’ neurofibromatosis program headed for NDA and updates from Astellas, Propella, BMS, Merck, Nature’s Toolbox, Apollomics and Avistone
BioCentury | May 19, 2022
Product Development

May 18 Quick Takes: Enanta tumbles after hours after missing RSV endpoint

Plus: House E&C passes user fee bill and updates from Hengrui, Laekna, Prenetics, Enanta and more
BioCentury | Oct 1, 2021
Distillery Therapeutics

SQLE identified as prostate cancer target

BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

Who's doing what in next-generation targeted radiotherapies for cancer
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

Why the treatment paradigm for prostate cancer could soon see a shake-up
BioCentury | Feb 6, 2019
Distillery Therapeutics

Cancer

BioCentury | Dec 8, 2018
Regulation

Path to opioid-free pain relief

How clarity on outcomes could spur development of non-opioid analgesics
Items per page:
1 - 10 of 183